Table 2

Multivariate analysis for estimation of the chemopreventive effect of metformin in diabetic patients

Diabetic patients (N=47 820)ORs (95% CI)p Value
Metformin use (user vs non-users)0.79 (0.75 to 0.83)<0.0001
Age (each incremental year)1.00 (1.00 to 1.00)0.3031
Gender (male vs female)1.06 (1.01 to 1.11)0.0216
Hepatitis B14.58 (13.28 to 16.02)<0.0001
Hepatitis C18.02 (16.40 to 19.79)<0.0001
Liver cirrhosis3.14 (2.62 to 3.75)<0.0001
End stage renal failure0.68 (0.63 to 0.73)<0.0001
DM duration (each incremental year)0.92 (0.91 to 0.93)<0.0001
DM control (each incremental visit per year)1.00 (1.00 to 1.01)0.6694
Other OHA agents use (users vs non-users)1.20 (1.10 to 1.30)<0.0001
Thiazolidinediones use (users vs non-users)0.76 (0.70 to 0.81)<0.0001
Insulin use (users vs non-users)4.37 (4.17 to 4.59)<0.0001
  • DM, diabetes mellitus; OHA, oral hypoglycaemic agent.